Thus, the third-generation (3G), more central nervous system (CNS)-penetrant, irreversible EGFR-TKI, osimertinib, which selectively inhibits both EGFR-TKI-sensitizing mutations and T790M without binding wild-type (wt) EGFR, is approved worldwide as the SOC for second-line therapy of advanced T790M-positive NSCLC, given its superior efficacy over platinum-pemetrexed therapy in this setting, including in patients with CNS metastases [20,21]. Here, EGFR is linked to non-small cell lung carcinoma.